Wellington Management Group LLP Has $180,000 Holdings in PepGen Inc. (NASDAQ:PEPG)

Wellington Management Group LLP boosted its holdings in PepGen Inc. (NASDAQ:PEPG) by 17.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,506 shares of the company’s stock after buying an additional 6,989 shares during the quarter. Wellington Management Group LLP owned approximately 0.15% of PepGen worth $180,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of PEPG. Dimensional Fund Advisors LP boosted its stake in PepGen by 26.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,102 shares of the company’s stock valued at $216,000 after buying an additional 11,870 shares in the last quarter. Northern Trust Corp boosted its stake in shares of PepGen by 5.4% during the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company’s stock valued at $595,000 after purchasing an additional 7,984 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of PepGen by 54.7% during the fourth quarter. Bank of America Corp DE now owns 53,868 shares of the company’s stock valued at $204,000 after purchasing an additional 19,056 shares in the last quarter. Bridgeway Capital Management LLC boosted its stake in shares of PepGen by 103.1% during the fourth quarter. Bridgeway Capital Management LLC now owns 98,900 shares of the company’s stock valued at $375,000 after purchasing an additional 50,200 shares in the last quarter. Finally, Corton Capital Inc. acquired a new stake in shares of PepGen during the fourth quarter valued at about $68,000. 58.01% of the stock is owned by institutional investors and hedge funds.

PepGen Trading Up 5.6%

Shares of PEPG stock opened at $1.50 on Monday. The business’s 50-day moving average price is $1.41 and its 200-day moving average price is $2.37. PepGen Inc. has a 12 month low of $0.88 and a 12 month high of $19.30. The firm has a market capitalization of $49.08 million, a price-to-earnings ratio of -0.50 and a beta of 1.30.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). On average, sell-side analysts predict that PepGen Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Activity at PepGen

In other news, CEO James G. Mcarthur bought 41,500 shares of the firm’s stock in a transaction on Tuesday, April 8th. The stock was acquired at an average price of $1.15 per share, with a total value of $47,725.00. Following the transaction, the chief executive officer now owns 103,913 shares of the company’s stock, valued at $119,499.95. This trade represents a 66.49% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 59,875 shares of company stock worth $71,610 over the last ninety days. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright cut their price target on PepGen from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, May 29th.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.